ZetaGen Therapeutics

Syracuse, NY · Founded 2015 · Privately Held (backing)

Developer of a small molecule-based osteoinductive technology designed to suspend cancer, inhibit pain and regenerate bone. ZetaGen Therapeutics is based in Syracuse, NY and was founded in 2015. It was valued at $180 million at its later-stage round in Jan 2025, the last priced event on record. It has raised $52.5 million across 4 recorded rounds; the latest was a $12.9 million early-stage round in Jan 2025.

PMV mark · valuation
$180.0M
Oct 2026
Priced at
its later-stage round
Jan 2025
Total raised
$52.5M
Last round
Early Stage VC
Jan 2025

Who backs ZetaGen Therapeutics?

5 investors
InvestorType
National Institutes of HealthOther
New York VenturesVenture capital
AJU IB Investment—
JStar Capital—
National Institutes of Arthritis and Musculoskeletal Diseases—
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

ZetaGen Therapeutics investors

5 investors are on record for ZetaGen Therapeutics, including National Institutes of Health, New York Ventures, AJU IB Investment and JStar Capital. The early-stage round in Jan 2025 drew 35 investors.

Free account
More of ZetaGen Therapeutics with a free account
  • ·Watch ZetaGen Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 5 firms already write checks for companies like ZetaGen Therapeutics. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View